Cerivastatin

Summary

Cerivastatin (CHEMBL1477) is an approved small molecule (ATC C10AA06) targeting HMGCR; indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C10AA06
• Targets: 1 (HMGCR)
• Indications: 1 condition
• Chemistry: 459.5 Da · C26H34FNO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1477
Name	Cerivastatin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	446156
ChEBI	CHEBI:3558
ATC	C10AA06
Molecular formula	C26H34FNO5
Molecular weight	459.5
InChIKey	SEERZIQQUAZTOL-ANMDKAQQSA-N

SMILES: CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O

IUPAC name: (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)-3-pyridinyl]-3,5-dihydroxyhept-6-enoic acid

ChEBI definition: (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.

Also known as: Cerivastatin, Cerivastatina, Cerivastatine, Lipobay, cerivastatin, SID50111694, CERIVASTATINE, CERIVASTATIN

Parent form; salt/anhydrous children: CHEMBL1200563

Patent coverage: 7,903 distinct patent families (32,039 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 31,957 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HMGCR	hydroxymethylglutaryl-CoA reductase	Competitive	8	84.4%	P04035

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Nuclear receptor ROR-gamma, Estrogen receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor, 3’,5’-cyclic-AMP phosphodiesterase 4A, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HMGCR	10.07	IC50	0.09	nM	CHEMBL_ACT_7703291
P51639	8.55	IC50	2.8	nM	CHEMBL_ACT_1974259
P51639	8.55	IC50	2.8	nM	CHEMBL_ACT_2064273
P51639	8.01	IC50	9.8	nM	CHEMBL_ACT_2218033
HMGCR	8	IC50	10	nM	CHEMBL_ACT_1439883

Target pathways

Aggregated over 1 target gene(s): HMGCR.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Cholesterol biosynthesis	1	HMGCR
PPARA activates gene expression	1	HMGCR
Activation of gene expression by SREBF (SREBP)	1	HMGCR
EGR2 and SOX10-mediated initiation of Schwann cell myelination	1	HMGCR
Lanosterol biosynthesis	1	HMGCR

Dominant GO biological processes

GO term	Targets
cholesterol biosynthetic process	1
isoprenoid biosynthetic process	1
visual learning	1
coenzyme A metabolic process	1
sterol biosynthetic process	1
negative regulation of protein catabolic process	1
negative regulation of protein secretion	1
long-term synaptic potentiation	1
regulation of ERK1 and ERK2 cascade	1
negative regulation of amyloid-beta clearance	1
lipid metabolic process	1
steroid biosynthetic process	1
steroid metabolic process	1
cholesterol metabolic process	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 8 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
ATORVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
LOVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
PITAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
PRAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
ROSUVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
SIMVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
CISAPRIDE	ChEMBL	Phase 4 (approved)	HMGCR
FLUVASTATIN	ChEMBL	Phase 4 (approved)	HMGCR
TANNIC ACID	ChEMBL	Phase 4 (approved)	HMGCR
GLENVASTATIN	ChEMBL	Phase 2	HMGCR
MEGLUTOL	ChEMBL	Phase 2	HMGCR
MEVASTATIN	ChEMBL	Phase 2	HMGCR
Vorinostat	PubChem	Approved	HMGCR